Zurcher Kantonalbank (Zurich Cantonalbank) Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$144.95 - $152.29 $51,022 - $53,606	352 Added 4.81%	7,673 $1.16 Million
Q2 2022 Aug 09, 2022	SELL	$83.14 - $145.99 $48,553 - $85,258	-584 Reduced 7.39%	7,321 $1.07 Million
Q1 2022 Apr 21, 2022	SELL	$110.08 - $142.92 $117,785 - $152,924	-1,070 Reduced 11.92%	7,905 $937,000
Q4 2021 Feb 01, 2022	BUY	$99.73 - $148.48 $355,238 - $528,885	3,562 Added 65.8%	8,975 $1.24 Million
Q2 2021 Jul 30, 2021	SELL	$65.78 - $105.02 $23,746 - $37,912	-361 Reduced 6.25%	5,413 $525,000
Q1 2021 May 03, 2021	SELL	$64.07 - $91.75 $64,582 - $92,484	-1,008 Reduced 14.86%	5,774 $395,000
Q4 2020 Jan 28, 2021	BUY	$65.07 - $98.24 $90,121 - $136,062	1,385 Added 25.66%	6,782 $581,000
Q2 2020 Jul 28, 2020	BUY	$29.01 - $74.23 $57,787 - $147,866	1,992 Added 58.5%	5,397 $395,000
Q4 2019 Jan 21, 2020	BUY	$40.86 - $57.65 $32,156 - $45,370	787 Added 30.06%	3,405 $185,000
Q3 2019 Oct 18, 2019	BUY	$37.38 - $49.47 $13,531 - $17,908	362 Added 16.05%	2,618 $109,000
Q2 2019 Jul 30, 2019	BUY	$39.79 - $67.01 $43,649 - $73,509	1,097 Added 94.65%	2,256 $99,000
Q1 2019 Apr 29, 2019	SELL	$34.52 - $53.29 $15,499 - $23,927	-449 Reduced 27.92%	1,159 $60,000
Q3 2018 Nov 09, 2018	BUY	$32.79 - $43.0 $20,231 - $26,531	617 Added 62.26%	1,608 $60,000
Q2 2018 Aug 06, 2018	SELL	$23.62 - $42.29 $11,054 - $19,791	-468 Reduced 32.08%	991 $39,000
Q4 2017 Jan 31, 2018	BUY	$20.44 - $35.56 $29,821 - $51,882	1,459	1,459 $39,000

Others Institutions Holding BHVN

# of Institutions

Shares Held

792K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account